Survival rates for idiopathic pulmonary fibrosis are worse than all solid cancers except for lung and pancreatic cancer. | ...
Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...
Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...
its experimental therapy for serious lung disease idiopathic pulmonary fibrosis (IPF). The study will use the e-ILD platform to process high-resolution chest computed tomography (HRCT) images ...
Veracyte (VCYT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Puneet Souda ...
June 11, 2024 — Chronic lung ... pulmonary disease (COPD) prevalence and outcomes between the sexes. According to a ... Researchers Identify Protein Connected to Aging and Idiopathic Pulmonary ...
Some of the patients may require lung transplantation. There are about 200 different conditions that are categorized under ILD. The conditions commonly considered as ILDs include various disorders ...
Shares of Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) gapped up before the market opened on Thursday following a better than expected earnings announcement. The stock had previously closed at ...
It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers ... OEC candidates for idiopathic pulmonary fibrosis; liver regeneration ...
For example, until recently, there was little that could be done to treat idiopathic pulmonary fibrosis. Today ... those living with COPD and those who have had lung cancer surgery. When the condition ...